Owners, management and financials
CVR: 29615861
Previous names: Q-VIGILANCE ApS
DKK 1,163,256
Gross profit
Net result: DKK 122,320
MAC ANDORBY ApS (100%)
CVR · view owners
Nusret Asanovski
CVR · view management
Active
Founded 23 May 2006
CVR · view overview
1 employee
CVR · 2026
Name registered: GXP PHARMAID ApS
CVR · 25/09/2008
View the full event history
GXP PHARMAID ApS is a Danish company of the type Anpartsselskab based in Brønshøj, founded in 2006. The company is registered under the industry Anden teknisk rådgivning. The company was previously named Q-VIGILANCE ApS. The management consists of Nusret Asanovski. The company is owned by MAC ANDORBY ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,163,256 and a net result of DKK 122,320 compared with DKK 216,532 the year before. Equity in the 2025 report amounted to DKK 1,218,531.
Source: annual report 2025, Danish Business Authority
GXP PHARMAID ApS has shown a recovery in profitability over the past few years, with profits increasing from a loss of 503,961 DKK in 2021 to a profit of 122,320 DKK in 2025. Gross profit has also improved significantly, rising from 349,682 DKK in 2022 to 1,163,256 DKK in 2025, indicating a positive trend in operational efficiency. The company's equity has steadily increased, reaching 1,218,531 DKK in 2025, which reflects a strengthening financial position. However, the lack of disclosed revenue figures raises concerns about transparency and overall market performance within the technical consulting industry.
AI-generated summary · Generated 14/08/2026
Selskabets formål er at levere konsulentbistand til den farmaceutiske og bioteknologiske industri samt hermed beslægtet virksomhed efter direktionens skøn.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 1.2 mio. | 122 t. | 1.8 mio. | 1.2 mio. | 1 | |
| 202401/01/2024 – 31/12/2024 | 1.3 mio. | 217 t. | 1.8 mio. | 1.1 mio. | 1 | |
| 202301/01/2023 – 31/12/2023 | 1.2 mio. | 513 t. | 1.7 mio. | 880 t. | 1 | |
| 202201/01/2022 – 31/12/2022 | 350 t. | -325 t. | 1.2 mio. | 367 t. | 1 | |
| 202101/01/2021 – 31/12/2021 | 363 t. | -504 t. | 1 mio. | 691 t. | 2 | |
| 202001/01/2020 – 31/12/2020 | 2.8 mio. | 960 t. | 3 mio. | 1.7 mio. | 3 | |
| 201901/01/2019 – 31/12/2019 | 763 t. | -169 t. | 1.4 mio. | 735 t. | 1 | |
| 201801/01/2018 – 31/12/2018 | 1.1 mio. | 217 t. | 1.9 mio. | 904 t. | 1 | |
| 201701/01/2017 – 31/12/2017 | 1.4 mio. | 142 t. | 1.9 mio. | 687 t. | 1 | |
| 201601/01/2016 – 31/12/2016 | 1.6 mio. | 97 t. | 1.5 mio. | 544 t. | - | |
| 201501/01/2015 – 31/12/2015 | 1.9 mio. | -667 t. | 1.7 mio. | 447 t. | - | |
| 201401/01/2014 – 31/12/2014 | 3.6 mio. | 380 t. | 2.6 mio. | 1.1 mio. | - | |
| 201301/01/2013 – 31/12/2013 | 2.3 mio. | 451 t. | 2.6 mio. | 1.1 mio. | - | |
| 201201/01/2012 – 31/12/2012 | 2.1 mio. | - | - | - | - |
Compared to 1.487 companies in Anden teknisk rådgivning
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of GXP PHARMAID ApS is 29615861.
GXP PHARMAID ApS is owned by MAC ANDORBY ApS.
The management of GXP PHARMAID ApS consists of Nusret Asanovski.
In 2025, GXP PHARMAID ApS reported a gross profit of DKK 1,163,256.
GXP PHARMAID ApS had 1 employee in 2026 according to the Danish CVR register.
GXP PHARMAID ApS was founded on 23 May 2006.
Claim this page to add your logo and social links. Free to get started.
GXP PHARMAID ApS has published its annual report for 2025. Gross profit came to DKK 1,163,256, and the net result was DKK 122,320.
GXP PHARMAID ApS has published its annual report for 2024. Gross profit came to DKK 1,340,825, and the net result was DKK 216,532.
GXP PHARMAID ApS has published its annual report for 2023. Gross profit came to DKK 1,192,153, and the net result was DKK 513,163.
GXP PHARMAID ApS has published its annual report for 2022. Gross profit came to DKK 349,682, and the net result was DKK -324,771.
As of June 15, 2023, AIDER Godkendt Revisionsaktieselskab has been appointed auditor of GXP PHARMAID ApS.
As of June 15, 2023, EMIT P/S has stepped down as auditor of GXP PHARMAID ApS.
GXP PHARMAID ApS has published its annual report for 2021. Gross profit came to DKK 363,324, and the net result was DKK -503,961.
GXP PHARMAID ApS has published its annual report for 2020. Gross profit came to DKK 2,798,982, and the net result was DKK 960,283.
GXP PHARMAID ApS has published its annual report for 2019. Gross profit came to DKK 762,547, and the net result was DKK -168,984.
GXP PHARMAID ApS has published its annual report for 2018. Gross profit came to DKK 1,148,568, and the net result was DKK 217,265.
GXP PHARMAID ApS has published its annual report for 2017. Gross profit came to DKK 1,410,169, and the net result was DKK 142,289.
As of December 11, 2017, EMIT P/S has been appointed auditor of GXP PHARMAID ApS.
As of December 11, 2017, TIMEVISION FREDERIKSBERG REGISTRERET REVISIONSAKTIESELSKAB has stepped down as auditor of GXP PHARMAID ApS.
GXP PHARMAID ApS has published its annual report for 2016. Gross profit came to DKK 1,632,757, and the net result was DKK 97,377.
GXP PHARMAID ApS has published its annual report for 2015. Gross profit came to DKK 1,896,044, and the net result was DKK -667,129.
GXP PHARMAID ApS has published its annual report for 2014. Gross profit came to DKK 3,604,083, and the net result was DKK 380,379.
As of August 12, 2014, Nusret Asanovski has left the board of directors of GXP PHARMAID ApS.
As of August 12, 2014, Jonas Evjenios Markou has left the board of directors of GXP PHARMAID ApS.
As of August 12, 2014, Mogens Birch-Larsen has left the board of directors of GXP PHARMAID ApS.
GXP PHARMAID ApS has published its annual report for 2013. Gross profit came to DKK 2,306,234, and the net result was DKK 450,698.
As of October 30, 2013, Nusret Asanovski has joined the board of directors of GXP PHARMAID ApS.
As of October 30, 2013, Jonas Evjenios Markou has joined the board of directors of GXP PHARMAID ApS.
As of October 30, 2013, Mogens Birch-Larsen has joined the board of directors of GXP PHARMAID ApS.
GXP PHARMAID ApS has published its annual report for 2012.
As of July 9, 2012, TIMEVISION FREDERIKSBERG REGISTRERET REVISIONSAKTIESELSKAB has been appointed auditor of GXP PHARMAID ApS.
As of July 9, 2012, LST DK Holding ApS has stepped down as auditor of GXP PHARMAID ApS.
On September 25, 2008, the company changed its name from Q-VIGILANCE ApS to GXP PHARMAID ApS.
As of December 7, 2006, MAC ANDORBY ApS is registered as an owner of GXP PHARMAID ApS with an ownership share of 100%.
As of May 23, 2006, LST DK Holding ApS has been appointed auditor of GXP PHARMAID ApS.
As of May 23, 2006, Nusret Asanovski is registered as director of GXP PHARMAID ApS.
GXP PHARMAID ApS was founded on May 23, 2006.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 37107816
CVR 41654988
CVR 16539740
CVR 34922578
CVR 45530531
